Business Context and Reporting Period
This Form 10-Q covers Eli Lilly and Company for the quarter ended March 31, 1998. The company is a global pharmaceutical and life-sciences firm headquartered in Indianapolis, Indiana. As of April 30, 1998, there were 1,107,425,186 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 1998 | Q1 1997 |
|---|---|---|
| Net Sales | $2,269.1 million | $1,953.0 million |
| Cost of Sales | $602.1 million | $541.3 million |
| Gross Margin | 73.5% | 72.3% |
| Research & Development | $364.7 million | $301.2 million |
| Marketing & Administrative | $566.0 million | $471.7 million |
| Income Before Taxes | $704.4 million | $576.8 million |
| Net Income | $521.1 million | $432.6 million |
| Diluted EPS (Net Income) | $0.46 | $0.38 |
| Cash and Cash Equivalents (End of Period) | $1,264.7 million | $1,042.1 million |
| Total Debt (Short-term + Long-term) | $2,557.2 million | Filing text does not provide a clear comparative total for Q1 1997 |
| Net Cash from Operating Activities | $57.3 million | $303.7 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 16% year-over-year, driven by a 20% increase in U.S. sales and a 9% increase in international sales. Worldwide pharmaceutical sales rose 17%.
- Product Performance: Sales growth was led by newer products Gemzar, ReoPro, and Zyprexa, alongside Prozac. Zyprexa sales increased $182 million. Conversely, anti-infective sales declined 14% due to generic competition and exchange rates.
- Profitability: Net income rose 20% to $521.1 million. Gross margin improved to 73.5% due to favorable product mix and productivity gains.
- Expenses: Operating expenses increased 20%, with R&D up 21% and Marketing/Admin up 20% due to new product launches and IT initiatives.
- Cash Flow: Net cash from operating activities decreased significantly to $57.3 million from $303.7 million, primarily due to changes in operating assets and liabilities. Cash and equivalents dropped $682.8 million during the quarter, largely due to $220.7 million in dividends and $461.9 million in stock repurchases.
- Extraordinary Item: A one-time loss of $7.2 million (net of tax) was recorded due to the early redemption of debt.
Guidance, Outlook, and Risks
- Management Outlook: Management believes cash generated from operations and available cash will be sufficient to fund 1998 operating needs, including debt service and capital expenditures.
- Leadership Transition: Chairman and CEO Randall L. Tobias plans to retire at the end of 1998. Sidney Taurel was elected President and CEO effective July 1, 1998.
- Year 2000 Compliance: The company is modifying computer systems for Year 2000 readiness. Management believes incremental costs will not materially affect financial position through 1999, though failure to resolve issues could be material.
- Legal Contingencies:
- Product Liability: Ongoing lawsuits regarding diethylstilbestrol and Prozac. Accruals of approximately $342 million are recorded, with estimated insurance recoveries of $235 million.
- Antitrust: Settlements reached in federal and state pricing litigation with retail pharmacies; some cases remain pending.
- Patent Litigation: Barr Laboratories and Geneva Pharmaceuticals have challenged Prozac patents. An unfavorable outcome could have a material adverse effect.
- Environmental: Accruals exist for Superfund cleanup costs and remediation of company sites.
Investor Verification Checklist
- Verify the sustainability of sales growth for Zyprexa, Gemzar, and ReoPro versus the decline in anti-infectives and Humulin.
- Monitor the outcome of patent litigation regarding Prozac, as generic entry could materially impact future revenue.
- Review the status of antitrust and product liability settlements to assess potential changes in the $342 million accrual or $235 million insurance recovery.
- Assess the impact of the significant decrease in operating cash flow ($57.3M vs $303.7M) on future liquidity and capital allocation.
- Confirm the timeline and cost implications of Year 2000 system modifications.